GlassScriptPhysician profile
Jamie L Mull
NPI 1467892166
$10,117.95
in general payments reported to CMS, 2019-2025
33 companies · $1,461 in 2025
The $1,461 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $883 · 2020: $466 · 2021: $1,477 · 2022: $1,624 · 2023: $2,326 · 2024: $1,882 · 2025: $1,461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,570 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,569.51 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,229.29 | 2019-2025 | |
| Janssen Biotech, INC. | $1,254.37 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $1,122.91 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $827.33 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Genzyme Corporation | $547.48 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $540.14 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $526.40 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $490.00 | 2019-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $398.37 | 2021-2025 | Dupixent, Libtayo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $357.55 | 2019-2025 | Jublia, Cabtreo |
| Pfizer INC. | $286.63 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $234.99 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $224.90 | 2024-2025 | Nemluvio, Aklief |
| Incyte Corporation | $212.46 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $208.11 | 2019-2025 | Adbry, Anzupgo, Spevigo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $153.32 | 2019-2025 | Bimzelx, Cimzia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.52 | 2022-2024 | Spevigo |
| Genentech USA, INC. | $70.15 | 2019-2021 | |
| Organogenesis INC. | $66.56 | 2023-2025 | Puraply, Cygnus Dual |
| Dermavant Sciences, INC. | $44.39 | 2023 | Vtama |
| Verrica Pharmaceuticals INC. | $24.88 | 2025 | Ycanth |
| Vyne Pharmaceuticals INC. | $22.14 | 2021 | |
| Botanix Sb INC | $21.26 | 2025 | Sofdra |
| Almirall LLC | $21.18 | 2019 | |
| Prugen, INC. Pharmaceuticals | $20.30 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $19.57 | 2019 | |
| Biofrontera INC. | $17.54 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Aclaris Therapeutics, INC. | $14.54 | 2019 | |
| Celgene Corporation | $13.25 | 2019 | |
| Merck Sharp & Dohme LLC | $12.14 | 2019 | |
| Reprise Biomedical, INC. | $11.92 | 2025 | Miro3d |
| Helsinn Therapeutics (U.S.), INC. | $11.92 | 2019 | |
| Organon LLC | $11.44 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Mull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.